ZD1839 (‘Iressa’), an orally-active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), is well tolerated in combination with gemcitabine and cisplatin, in patients with advanced solid tumours: preliminary tolerability, efficacy and pharmacokinetic results
G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G.J. Peters; W.J.F. van der Vijgh; R. Smith; A. Fandi; S. Averbuch
- 作者G. Giaccone; J.L. Gonzales-Larriba; E.F. Smit; A.T. van Oosterom; M. Martins; G.J. Peters; W.J.F. van der Vijgh; R. Smith; A. Fandi; S. Averbuch
- 卷第37卷
- 印刷ISSN0959-8049
- 文件大小338.40KB
- 发表时间2001
- DOI10.1016/s0959-8049(01)80594-3